- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Emerging Molecular Biomarkers in Ovarian Cancer
A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including microsatellite instability (MSI), tumor mutational burden (TMB), HER2, p53, KRAS, and CCNE amplification.
EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer
EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer
EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer
EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer
EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer
EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing
EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
EP: 8.The Role of Novel Targeted Therapies
EP: 9.The Use of PARP Inhibitors in Ovarian Cancer
EP: 10.Earlier Introduction of Antibody-Drug Conjugates
EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients
EP: 12.Single-Agent Vs Combination Regimens
EP: 13.The Potential Impact of Investigational Therapies
EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer
EP: 15.Overcoming Payer-Related Barriers for Optimal Care in Patients With Ovarian Cancer
EP: 16.The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer
EP: 17.Streamlining Biomarker-Driven Therapy Decisions to Prevent Delays
EP: 18.The Effect of Adverse Event Profiles on Treatment Decisions
EP: 19.Evaluating Long-Term Safety Considerations for Targeted Therapies in Ovarian Cancer
Video content above is prompted by the following:
Emerging Molecular Biomarkers Beyond BRCA/HRD
Several important biomarkers guide ovarian cancer treatment beyond BRCA and HRD:
Tumor-agnostic biomarkers:
- MSI/mismatch repair deficiency and TMB: Predict response to immunotherapy
- HER2 (immunohistochemistry): Approved April 2024 for trastuzumab deruxtecan (FDA approved for 3+ expression; National Comprehensive Cancer Network recommends for 2+ also)
Diagnostic and predictive biomarkers:
- p53: Distinguishes high-grade from low-grade serous ovarian cancer
- KRAS: Expected to become an integrated biomarker for upcoming MEK/FAK inhibitor combination therapy in low-grade serous ovarian cancer
- CCNE1 amplification: Mutually exclusive with BRCA mutations, associated with platinum resistance, with targeted therapies in development
The field continues to advance through collaborative research networks, including GOG Foundation and ENGOT, developing biomarker-directed treatments for gynecologic cancers.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
